What's driving the UK tax insurance boom?
Lower prices, deeper expertise and broader risk appetites are just some of the factors behind huge growth in the market.
Source: icaew.com
📰 Specialty Head News
Specialty Head News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Specialty Head. Real-time updates on events, politics, business and more.
First European ustekinumab biosimilar to Stelara approved
The European Commission has granted a marketing authorisation for Uzpruvo® in Europe, a biosimilar candidate to Stelara® . Ustekinumab biologic ...
Bryan Kim Russell Publishing European Commission Committee For Medicinal Products Human Use European Supplementary Protection Certificate Specialty Head
Source: marketscreener.com
STADA and Alvotech Secure Approval for Uzpruvo, Europe's First Ustekinumab Biosimilar to Stelara -January 10, 2024 at 03:31 am EST
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatology Authorization paves...
Source: marketscreener.com
STADA and Alvotech Secure Approval for Uzpruvo, Europe's
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology,...
Source: globenewswire.com
STADA and Alvotech's win first EU-approval for Stelara biosimilar - Pharmaceutical Technology
STADA and Alvotech’s Uzpruvo gained an EU marketing authorisation, allowing it to be sold in the European Economic Area in 2024.
Johnson Stelara Bryan Kim European Commission For Uzpruvo Committee For Medicinal Products Human Use Company Profiles Company Profile
Source: pharmaceutical-technology.com
European Biologics Regulatory Updates | Goodwin
Bayer’s aflibercept 8 mg recommended for approval in Europe: On November 10, 2023, Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
Source: jdsupra.com
STADA and Alvotech receive positive CHMP opinion for Europe's first ustekinumab biosimilar to Stelara - Alvotech (NASDAQ:ALVO)
CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo biosimilar is based on
Source: benzinga.com